Enjoy complimentary customisation on priority with our Enterprise License!
The Americas immunochemistry market size is estimated to grow by USD 3.62 billion, at a CAGR of 6.98% between 2023 and 2028. Recent advancements in antibody production, such as recombinant antibody technologies, enhance immunochemistry assays by delivering highly specific monoclonal antibodies with minimal variation. Automated immunoassay systems streamline workflows, reducing time, labor, and errors by automating key steps like washing and detection. Microplate reader innovations, like EDR technology in devices such as the CLARIOstar Plus, improve assay speed, sensitivity, and efficiency. These innovations propel growth in the immunochemistry market in Americas, enabling the development of more reliable assays for research, diagnostics, and therapeutics, with further expansion expected as technologies evolve.
The report also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historical data from 2018-2022, besides analyzing the current market scenario.
To learn more about this market forecast report, Download Report Sample
The global immunohistochemistry market is witnessing substantial growth, driven by advancements in diagnostic accuracy and personalized medicine for diseases like cancer and cardiovascular disorders. Healthcare professionals increasingly rely on automation, digital imaging, and cutting-edge technologies such as RNA sequencing and machine learning to enhance disease diagnosis and treatment. Products like VENTANA DP 600 and immunochemistry products are pivotal in cancer detection and treatment, especially for conditions like non-small-cell lung cancer. With the rise of mutation-specific immunochemistry tests and AI algorithms, the market is poised for further expansion in clinical diagnostics and therapeutics.
The market share growth by the consumables segment will be significant during the forecast period. The consumable product segment of the immunochemistry market in Americas includes reagents, assay kits, antibodies, substrates, buffers, and disposable items essential for immunochemical assays and diagnostics. Key products include immunoassay kits, antibodies, substrates/enzymes, buffers/diluents, and microplates/tubes.
Get a glance at the market contribution of various segments Download PDF Sample
The consumables segment was valued at USD 3.27 billion in 2018. Further, major market players like Bio Rad Laboratories Ltd., Thermo Fisher Scientific Inc., Merck KGaA, and PerkinElmer, Inc. offer diverse portfolios catering to research, clinical, and diagnostic needs. Product launches, driven by rising chronic diseases and investment in drug discovery, enhance assay performance and drive market growth. Additionally, demand for consumables in decentralized testing and rapid diagnostics contributes to segment expansion in the forecast period.
The infectious disease segment will account for the largest share of this segment.?The rise in infectious diseases across the Americas, including Zika, Ebola, and COVID-19, fuels demand for rapid immunochemistry diagnostics. Immunochemical assays like ELISA and lateral flow tests offer quick, scalable solutions for disease detection and surveillance. Increased cases of diseases like hepatitis A, B, and C in the US, and dengue in Brazil, underline the necessity for accurate diagnostics. Immunochemistry aids in early detection, containment, and public health initiatives, driving market growth during the forecast period.
Moreover, the cardiology segment is also showing significant growth during the forecast period. The rising prevalence of cardiovascular diseases (CVDs) drives demand for advanced immunochemistry diagnostics in the Americas. Factors like aging populations and sedentary lifestyles contribute to CVD incidence. Advanced immunochemistry technologies detect specific biomarkers linked to cardiac injury, inflammation, and dysfunction, aiding early diagnosis and personalized treatment. Leading vendors like Roche and Abbott offer key solutions like high-sensitive troponin assays and NT-proBNP tests, enhancing cardiology diagnostics. The segment is further boosted by product innovations and launches, driving market growth.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
Agilent Technologies Inc., Becton Dickinson and Co., Bio Rad Laboratories Inc., Bio Techne Corp., bioMerieux SA, Danaher Corp., DiaSorin SpA, Enzo Biochem Inc., F. Hoffmann La Roche Ltd., Fujirebio Holdings Inc., Grifols SA, Hologic Inc., Merck and Co. Inc., Mindray Bio medical Electronics Co. Ltd., PerkinElmer Inc., Quanterix Corp., Randox Laboratories Ltd., Siemens AG, Sysmex Corp., Thermo Fisher Scientific Inc., and Tosoh Corp.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The global immunohistochemistry market is experiencing significant growth, driven by the increasing prevalence of cancer diseases and chronic illnesses among the geriatric population. Pathologists rely on advanced techniques like transcriptome sequencing and mass spectrometric detection alongside traditional methods such as IHC (Immunochemistry) and IHC protocols to diagnose and treat diseases. Immunohistochemistry products, including antibodies and multiplexed IHC, play a crucial role in diagnostic tools and Anti-PD-1 immunotherapy development. Furthermore, the integration of artificial intelligence (AI) algorithms is revolutionizing immunohistochemistry analysis, enhancing accuracy and efficiency in disease diagnosis and treatment. Our researchers analyzed the market research and growth data with 2023 as the base year, along with the key market growth analysis, trends, and challenges. A holistic analysis of drivers, trends, and challenges will help companies refine their marketing strategies to gain a competitive advantage.
Increasing incidences of neurological disorders is the key factor driving the market. Patients with neurological disorders, including epilepsy, stroke, Parkinson's disease (PD) and brain tumors, have a high risk of developing a neurological disability. These disorders may also be fatal. These neurological disorders develop due to various factors such as bacterial and viral infections, genetic factors, and the lack of immune response. Furthermore, treating brain hemorrhage due to stroke and brain tumors is boosting the demand for neuroscience antibodies and assays.
Furthermore, major market players offering immunochemistry solutions for neurological disorders in the Americas include Roche's Elecsys Alzheimer's immunoassay, Siemens AG' IMMULITE neurology assays, and Bio-Rad Laboratories Ltd.'s MAGPIX multiplex immunoassay platform for neurological biomarker detection. These products enable clinicians and researchers to accurately diagnose neurological disorders, monitor disease progression, and evaluate treatment efficacy, which will contribute to the market growth during the forecast period.
Increasing number of clinical trials is the primary trend shaping the market. Clinical trials are essential for evaluating the safety and efficacy of new drugs, vaccines, and therapies across various medical specialties, including oncology, infectious diseases, autoimmune disorders, and cardiology. Immunochemistry assays play a crucial role in these trials by enabling the measurement of biomarkers, cytokines, antibodies, and other immune-related parameters to assess treatment response, disease progression, and patient outcomes. Further, immunoassays provide valuable insights into the biological mechanisms underlying diseases and treatment effects, facilitating the identification of novel therapeutic targets, optimization of treatment regimens, and stratification of patient populations.
Furthermore, regulatory agencies such as the FDA in the US require rigorous biomarker analysis and validation in clinical trials to ensure the reliability and reproducibility of study results. Immunochemistry assays, with their high sensitivity, specificity, and precision, meet these regulatory requirements and are widely used in clinical trial settings. Thus, an increase in the number of clinical trials will drive the demand for immunochemistry products and solutions, which will boost the growth of the market during the forecast period.
Lack of trained professionals is the major challenge that affects the market expansion. Effective translation of diagnostics from research to application results in the correct diagnosis of diseases. Diagnosis of diseases requires extensive analysis to interpret the correct results. Therefore, clinical laboratories require trained specialists in this field. However, the presence of these specialists is scarce in diagnostic centers and hospitals worldwide. Also, many times, high fixed costs are associated with bringing specialists in-house, especially for smaller medical facilities.
Most rural hospitals in the US face issues such as the lack of patient volume required to justify having specialists. Limited public funds, the allocation of a small portion of this funding to laboratories. Also, end-users such as hospitals and diagnostic centers need to invest heavily to increase the number of trained professionals by providing training to their employees on how to appropriately obtain accurate results from assays and kits testing by following the best practices applied in the diagnostics industry. Thus, such factors may impede market growth during the forecast period.
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. The market growth and forecasting also focus on adoption rates in different regions based on penetration. Furthermore, the market forecasting report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Customer Landscape
The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
The market is witnessing remarkable growth, fueled by advancements in Next Generation Sequencing (NGS) and FISH (Fluorescence In Situ Hybridization) technologies. As Companion diagnostics gain prominence in personalized medicine, in vitro diagnostic medical devices are becoming integral to hospital and diagnostic centers and CROs (Contract Research Organizations). The market is driven by rising cases of chronic diseases, including nephrological diseases, autoimmune conditions, and cardiovascular diseases. Monoclonal antibodies, Fc-fusion, and antibody-drug conjugates are pivotal in combating infectious diseases and managing chronic conditions like diabetes mellitus and autoimmune diseases. With innovations like PathAI and HER2 testing with kits, the market continues to evolve to meet the diagnostic facilities needs of hospitals & diagnostic laboratories worldwide.
Americas Immunochemistry Market Scope |
|
Report Coverage |
Details |
Page number |
160 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 6.98% |
Market Growth 2024-2028 |
USD 3.62 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
6.42 |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Abbott Laboratories, Agilent Technologies Inc., Becton Dickinson and Co., Bio Rad Laboratories Inc., Bio Techne Corp., bioMerieux SA, Danaher Corp., DiaSorin SpA, Enzo Biochem Inc., F. Hoffmann La Roche Ltd., Fujirebio Holdings Inc., Grifols SA, Hologic Inc., Merck and Co. Inc., Mindray Bio medical Electronics Co. Ltd., PerkinElmer Inc., Quanterix Corp., Randox Laboratories Ltd., Siemens AG, Sysmex Corp., Thermo Fisher Scientific Inc., and Tosoh Corp. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by Application
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.